5-Loxin
Best for
Reduce everyday pain intensity
Likely benefit · 100–999 mg/day for 4–17 weeks · 3 meta-analyses , n=5.3k
22 papers · 6 claims · 47 outcomes scored · 5 positive
Outcomes
What 5-loxin actually does, by outcome
Each row is one outcome with effect size, evidence base, the dose that worked in trials, and time to first effect. Magnitude tiers come from native-unit MCID where available, Cohen's d otherwise.
Lower intensity, fewer flares, and longer stretches of relief.
Bathing, dressing, climbing stairs, and daily tasks stay within reach.
Less pain, less stiffness, quieter inflammatory signals inside the joint.
Joints move more freely, especially after rest or first thing in the morning.
Your joints stop being the first thing you notice every morning.
Your spine loosens up faster so bending and sitting stop being battles.
| Outcome | Effect | Evidence | Dose | Weeks | Rank |
|---|---|---|---|---|---|
| Reduce everyday pain intensity Likely benefit | | 5 meta-analyses n=5.3k Meta-analyzed | 100–999 mg | 4–17 wk | #2/55 |
| Stay independent longer with aging Likely benefit | | 1 meta-analysis n=4.3k Meta-analyzed | — | — | #3/25 |
| Ease arthritis pain and joint inflammation Likely modest benefit | | 8 meta-analyses n=919 Meta-analyzed | 100–999 mg | 4–13 wk | #4/21 |
| Loosen stiff joints Likely modest benefit | | 4 meta-analyses n=406 Meta-analyzed | 100–250 mg | 4–13 wk | #2/9 |
| Ease joint pain Faint early signal | | 4 meta-analyses n=386 Meta-analyzed | 100–999 mg | 8–13 wk | #6/18 |
| Ease ankylosing spondylitis symptoms Not enough research | | 1 RCT n=— | 400 mg | 4 wk | — |
Recommended 5-Loxin products
Real products that dose 5-Loxin where the research does, in a clean formulation, from brands we've audited. We only list ones we'd stand behind.
-
Pure Encapsulations
Boswellia AKBA
Well dosed 100 mg/day A formulaBrand audit 78/100
-
Swanson
Boswellia serrata Extract 125 mg
Well dosed 250 mg/day B formulaBrand audit 69/100
-
SuperSmart
5-Loxin 200 mg
Well dosed 400 mg/day B formulaBrand audit 63/100
-
Pure Encapsulations
Phyto-4
Well dosed 100 mg/day B formulaBrand audit 78/100
-
SuperSmart
Inflarelief Formula
Well dosed 100 mg/day A formulaBrand audit 63/100
-
Puritan's Pride
Joint Health Formula plus Vitamin D
Well dosed 100 mg/day C formulaBrand audit 68/100
Chosen for adequate 5-Loxin dosing vs. the studied range, a clean formulation (grade A–C), and independent brand-quality audits. Not sponsored.
Risk profile
Adverse events and known drug interactions
Safety events
Sources
- 1. A pilot, randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the knee. (2019) ↑
- 2. Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis. (2020) ↑
- 3. Efficacy of Extracts of Oleogum Resin of Boswellia in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-Analysis. (2024) ↑
- 4. Comparative Effectiveness of Nutritional Supplements in the Treatment of Knee Osteoarthritis: A Network Meta-Analysis. (2025) ↑
- 5. A full-spectrum Boswellia serrata extract with enhanced bioavailability, and its co-delivered system with curcumin alleviate pain and stiffness associated with moderate spondylitis: a randomized double-blind, placebo-controlled, 3-arm study. (2025) ↑
- 6. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. (2008) ↑
- 7. Comparative efficacy and tolerability of 5-Loxin and AflapinAgainst osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study. (2010) ↑
- 8. Oral herbal therapies for treating osteoarthritis. (2014) ↑
- 9. Efficacy of curcumin and Boswellia for knee osteoarthritis: Systematic review and meta-analysis. (2018) ↑
- 10. Efficacy of Boswellia serrata Extract and/or an Omega-3-Based Product for Improving Pain and Function in People Older Than 40 Years with Persistent Knee Pain: A Randomized Double-Blind Controlled Clinical Trial. (2023) ↑
Generated August 14, 2026